Drug Company Receives FDA Fast-Track Approval for New Auto-Injector
New and Improved Delivery Method to Stop Cluster Seizures The Chicago based pharmaceutical company Xeris has recently received an FDA fast-track designation for its diazepam formulation which utilizes an auto-injector for quick and easy medication delivery. Diazepam is a drug used to treat acute repetitive seizures, also known as cluster seizures. Around 30 percent of […]
Ibuprofen Superior to Acetaminophen for Pain & Fever in Infants
Parents Worried about Autism/Co-Occurring Conditions Risk Can Chose Ibuprofen A new analysis comparing acetaminophen with another common pain reliever, ibuprofen, has found ibuprofen to be superior for the treatment of fever or pain in children younger than 2 years. It was associated with reduced temperature and less pain within the first 24 hours of treatment, […]
Free Webinar on Covid-19 for People with Disabilities
Presentation Will Be Given in Several Accessible Formats The Center for Inclusive Design and Innovation (CIDI) at Georgia Tech has partnered with the Centers for Disease Control and Prevention (CDC) Foundation to initiate a new project focusing on delivering accessible messages on COVID-19 to people with disabilities, their families, and caregivers! The target audiences for […]
Autism Research Institute Offers Free Webinars
Make sure to check out ARI’s fantastic list of upcoming webinars. A variety of important subjects will be covered in the next few months. Upcoming topics include social skills, early intervention, managing anxiety, gastrointestinal disorders, among others. ARI’s Webinar Information
Study Finds More Doctor Visits During Infancy for Children with ASD and ADHD
Electronic Medical Records Utilized to Examine Health Care Utilization Patterns A new study from Duke University shows that children who have an autism spectrum disorder (ASD) and/or attention deficit hyperactivity disorder (ADHD) diagnosis visited the doctor or hospital more often during their first year of life compared to non-affected children. This new study, featured in […]
CBD Transdermal Gel Shows Promise for Treating ASD
Encouraging Results from Phase 2 Trial Presented at Neurology Conference Last month, Zynerba Pharmaceuticals, Inc. presented a poster to the Joint 16th International Child Neurology Congress & 49th Annual Child Neurology Society Meeting which described data from their Phase 2 BRIGHT (An Open-Label Tolerability and Efficacy Study of ZYN002 Administered as Transdermal Gel to Children […]
